{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:44:02Z","timestamp":1785545042709,"version":"3.56.0"},"reference-count":50,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Cancer"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Health care system\u2013wide outcomes from routine treatment with erlotinib and gefitinib are incompletely understood.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n \n The aim of the study is to describe the effectiveness of erlotinib and gefitinib during the first decade of their routine use for treating advanced epidermal growth factor receptor (\n EGFR<\/jats:italic>\n ) mutation-positive nonsquamous non\u2013small cell lung cancer in the entire cohort of patients treated in Aotearoa New Zealand.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Patients were identified, and data collated from national pharmaceutical dispensing, cancer registration, and mortality registration electronic databases by deterministic data linkage using National Health Index numbers. Time-to-treatment discontinuation and overall survival were measured from the date of first dispensing of erlotinib or gefitinib and analyzed by Kaplan-Meier curves. Associations of treatment outcomes with baseline factors were evaluated using univariable and multivariable Cox regressions.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Overall, 752 patients were included who started treatment with erlotinib (n=418) or gefitinib (n=334) before October 2020. Median time-to-treatment discontinuation was 11.6 (95% CI 10.8\u201012.4) months, and median overall survival was 20.1 (95% CI 18.1\u201021.6) months. Shorter time-to-treatment discontinuation was independently associated with high socioeconomic deprivation (hazard ratio [HR] 1.3, 95% CI 1.1\u20101.5 compared to the New Zealand Index of Deprivation 1\u20104 group),\n EGFR<\/jats:italic>\n L858R mutations (HR 1.3, 95% CI 1.1\u20101.6 compared to exon 19 deletion), and distant disease at cancer diagnosis (HR 1.4, 95% CI 1.2\u20101.7 compared to localized or regional disease). The same factors were independently associated with shorter overall survival. Outcome estimates and predictors remained unchanged in sensitivity analyses.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Outcomes from routine treatment with erlotinib and gefitinib in New Zealand patients with advanced\n EGFR<\/jats:italic>\n -mutant nonsquamous non\u2013small cell lung cancer are comparable with those reported in randomized trials and other health care system\u2013wide retrospective cohort studies. Socioeconomic status,\n EGFR<\/jats:italic>\n mutation subtype, and disease extent at cancer diagnosis were independent predictors of treatment outcomes in that setting.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/65118","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T12:32:16Z","timestamp":1741005136000},"page":"e65118-e65118","source":"Crossref","is-referenced-by-count":1,"title":["Treatment Outcomes From Erlotinib and Gefitinib in Advanced Epidermal Growth Factor Receptor\u2013Mutated Nonsquamous Non\u2013Small Cell Lung Cancer in Aotearoa New Zealand From 2010 to 2020: Nationwide Whole-of-Patient-Population Retrospective Cohort Study"],"prefix":"10.2196","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9356-9965","authenticated-orcid":false,"given":"Phyu Sin","family":"Aye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1522-8433","authenticated-orcid":false,"given":"Joanne","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7749-8922","authenticated-orcid":false,"given":"George","family":"Laking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8731-5307","authenticated-orcid":false,"given":"Laird","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8752-1376","authenticated-orcid":false,"given":"Malcolm","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1596-1025","authenticated-orcid":false,"given":"Brendan","family":"Luey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9837-881X","authenticated-orcid":false,"given":"Stephen","family":"Delany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7198-6319","authenticated-orcid":false,"given":"Dean","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4116-4046","authenticated-orcid":false,"given":"Blair","family":"McLaren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4285-8143","authenticated-orcid":false,"given":"Elliott","family":"Brenman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4489-1947","authenticated-orcid":false,"given":"Jayden","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0437-8839","authenticated-orcid":false,"given":"Ross","family":"Lawrenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3210-8190","authenticated-orcid":false,"given":"Michael","family":"Arendse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7303-061X","authenticated-orcid":false,"given":"Sandar","family":"Tin Tin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5730-4791","authenticated-orcid":false,"given":"Mark","family":"Elwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2049-3059","authenticated-orcid":false,"given":"Philip","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7329-5503","authenticated-orcid":false,"given":"Mark James","family":"McKeage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"issue":"3","key":"R1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","journal-title":"CA Cancer J Clin"},{"issue":"10299","key":"R2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","journal-title":"Lancet"},{"issue":"21","key":"R3","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","journal-title":"N Engl J Med"},{"issue":"5676","key":"R4","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","journal-title":"Science"},{"issue":"36","key":"R5","doi-asserted-by":"publisher","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"25","key":"R6","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","journal-title":"N Engl J Med"},{"issue":"2","key":"R7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","journal-title":"Lancet Oncol"},{"issue":"8","key":"R8","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","journal-title":"Lancet Oncol"},{"issue":"3","key":"R9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","journal-title":"Lancet Oncol"},{"issue":"9","key":"R10","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/annonc\/mdv270","article-title":"First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study","volume":"26","author":"Wu","journal-title":"Ann Oncol"},{"issue":"5","key":"R11","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","journal-title":"Lancet Oncol"},{"issue":"11","key":"R12","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","journal-title":"Lancet Oncol"},{"issue":"2","key":"R13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","journal-title":"N Engl J Med"},{"issue":"27","key":"R14","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1200\/JCO.21.02641","article-title":"AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with exon 19 deletion or L858R mutations","volume":"40","author":"Lu","journal-title":"J Clin Oncol"},{"issue":"26","key":"R15","doi-asserted-by":"publisher","first-page":"4208","DOI":"10.1200\/JCO.23.00515","article-title":"Lazertinib versus gefitinib as first-line treatment in patients with -mutated advanced non-small-cell lung cancer: results from LASER301","volume":"41","author":"Cho","journal-title":"J Clin Oncol"},{"issue":"11","key":"R16","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","article-title":"Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study","volume":"15","author":"Seto","journal-title":"Lancet Oncol"},{"issue":"12","key":"R17","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","journal-title":"Lancet Oncol"},{"issue":"5","key":"R18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","article-title":"Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"20","author":"Saito","journal-title":"Lancet Oncol"},{"issue":"2","key":"R19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1200\/JCO.19.01488","article-title":"Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study","volume":"38","author":"Hosomi","journal-title":"J Clin Oncol"},{"issue":"2","key":"R20","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1200\/JCO.19.01154","article-title":"Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in -mutated lung cancer","volume":"38","author":"Noronha","journal-title":"J Clin Oncol"},{"issue":"6","key":"R21","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01100-2018","article-title":"Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer","volume":"52","author":"Cramer-van der Welle","journal-title":"Eur Respir J"},{"issue":"3","key":"R22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3978\/j.issn.2218-6751.2014.06.10","article-title":"Italian multicenter survey to evaluate the opinion of patients and their reference clinicians on the \u201ctolerance\u201d to targeted therapies already available for non-small cell lung cancer treatment in daily clinical practice","volume":"3","author":"Novello","journal-title":"Transl Lung Cancer Res"},{"issue":"5","key":"R23","doi-asserted-by":"publisher","first-page":"e576","DOI":"10.1016\/j.cllc.2019.05.003","article-title":"Outcome differences between first- and second-generation EGFR inhibitors in advanced EGFR mutated NSCLC in a large population-based cohort","volume":"20","author":"Lau","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"R24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0209709","article-title":"Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non\u2013small-cell lung cancer in the USA","volume":"14","author":"Li","journal-title":"PLoS ONE"},{"issue":"4","key":"R25","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/ijc.32841","article-title":"Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: a retrospective cohort study in Taiwan","volume":"147","author":"Hsieh","journal-title":"Int J Cancer"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.720687","article-title":"Association of EGFR tyrosine kinase inhibitor treatment with progression-free survival among Taiwanese patients with advanced lung adenocarcinoma and EGFR mutation","volume":"12","author":"Chen","journal-title":"Front Pharmacol"},{"issue":"6","key":"R27","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-001011","article-title":"Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients","volume":"5","author":"Pluzanski","journal-title":"ESMO Open"},{"issue":"12","key":"R28","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1080\/0284186X.2023.2274481","article-title":"Treatment outcomes of non-small cell lung cancers treated with EGFR tyrosine kinase inhibitors: a real-world cohort study","volume":"62","author":"Manninen","journal-title":"Acta Oncol"},{"issue":"6","key":"R29","doi-asserted-by":"publisher","first-page":"e647","DOI":"10.1016\/j.cllc.2020.05.019","article-title":"Nationwide real-world cohort study of first-line tyrosine kinase inhibitor treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer","volume":"21","author":"Gijtenbeek","journal-title":"Clin Lung Cancer"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100592","article-title":"Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in the Netherlands: a retrospective, nationwide registry study","volume":"27","author":"Gijtenbeek","journal-title":"Lancet Reg Health Eur"},{"issue":"5","key":"R31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251357","article-title":"Population-based incidence rates and increased risk of EGFR mutated non-small cell lung cancer in M\u0101ori and Pacifica in New Zealand","volume":"16","author":"Aye","journal-title":"PLOS ONE"},{"key":"R32","unstructured":"StatsNZ. URL: https:\/\/www.stats.govt.nz [Accessed 07-01-2025]"},{"issue":"5","key":"R33","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s11523-017-0515-4","article-title":"EGFR mutation testing of non-squamous NSCLC: impact and uptake during implementation of testing guidelines in a population-based registry cohort from Northern New Zealand","volume":"12","author":"McKeage","journal-title":"Target Oncol"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.2196\/51381","article-title":"Erlotinib or gefitinib for treating advanced epidermal growth factor receptor mutation-positive lung cancer in Aotearoa New Zealand: protocol for a national whole-of-patient-population retrospective cohort study and results of a validation substudy","volume":"13","author":"Aye","journal-title":"JMIR Res Protoc"},{"key":"R35","unstructured":"Prescribing information Tarceva (erlotinib) tablets. U.S. Food & Drug Administration. 2016. URL: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021743s025lbl.pdf [Accessed 16-01-2025]"},{"key":"R36","unstructured":"Prescribing information Iressa (gefitinib) tablets. U.S. Food & Drug Administration. 2021. URL: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/206995s004lbl.pdf [Accessed 16-01-2025]"},{"issue":"5","key":"R37","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/annonc\/mdz060","article-title":"Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer","volume":"30","author":"Blumenthal","journal-title":"Ann Oncol"},{"key":"R38","unstructured":"Salmond C Crampton P Atkinson J . NZDep2006 Index of Deprivation. Department of Public Health, University of Otago; 2007. URL: https:\/\/www.otago.ac.nz\/wellington\/otago020348.pdf [Accessed 11-01-2025]"},{"key":"R39","unstructured":"An urban\/rural profile. Statistics New Zealand. URL: https:\/\/datafinder.stats.govt.nz\/layer\/120965-urban-rural-2025\/ [Accessed 11-01-2025]"},{"issue":"7","key":"R40","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/MLR.0000000000000149","article-title":"Development of a pharmacy-based comorbidity index for patients with cancer","volume":"52","author":"Sarfati","journal-title":"Med Care"},{"key":"R41","unstructured":"Ethicity data protocols: HISO 10001:2017 version 1.1. Health New Zealand: Te Whatu Ora. 2017. URL: https:\/\/www.tewhatuora.govt.nz\/assets\/Our-health-system\/Digital-health\/Health-information-standards\/HISO-10001-2017-Ethnicity-Data-Protocols.pdf [Accessed 11-01-2025]"},{"issue":"14","key":"R42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143641","article-title":"A nationwide study on the impact of routine testing for mutations in advanced NSCLC reveals distinct survival patterns based on mutation subclasses","volume":"13","author":"Koopman","journal-title":"Cancers (Basel)"},{"issue":"5","key":"R43","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1093\/jjco\/hyw014","article-title":"Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients","volume":"46","author":"Inoue","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"R44","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jtho.2015.12.103","article-title":"Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs","volume":"11","author":"Lin","journal-title":"J Thorac Oncol"},{"issue":"17","key":"R45","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1200\/JCO.2014.58.1736","article-title":"Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis","volume":"33","author":"Lee","journal-title":"J Clin Oncol"},{"issue":"5","key":"R46","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1158\/0008-5472.CAN-06-4293","article-title":"Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib","volume":"67","author":"Mulloy","journal-title":"Cancer Res"},{"issue":"16","key":"R47","doi-asserted-by":"publisher","first-page":"8163","DOI":"10.1158\/0008-5472.CAN-06-0453","article-title":"Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib","volume":"66","author":"Carey","journal-title":"Cancer Res"},{"issue":"3","key":"R48","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.lungcan.2014.01.008","article-title":"Treatment and survival disparities in lung cancer: the effect of social environment and place of residence","volume":"83","author":"Johnson","journal-title":"Lung Cancer"},{"issue":"12","key":"R49","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1200\/JCO.20.02602","article-title":"Persistent disparity: socioeconomic deprivation and cancer outcomes in patients treated in clinical trials","volume":"39","author":"Unger","journal-title":"J Clin Oncol"},{"issue":"9529","key":"R50","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S0140-6736(06)68813-2","article-title":"What is the contribution of smoking and socioeconomic position to ethnic inequalities in mortality in New Zealand?","volume":"368","author":"Blakely","journal-title":"Lancet"}],"container-title":["JMIR Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cancer.jmir.org\/2025\/1\/e65118","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:29:56Z","timestamp":1785536996000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancer.jmir.org\/2025\/1\/e65118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":50,"URL":"https:\/\/doi.org\/10.2196\/65118","relation":{},"ISSN":["2369-1999"],"issn-type":[{"value":"2369-1999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"article-number":"v11i3e65118"}}